@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix prov: .
@prefix pav: .
@prefix orcid: .
@prefix codebase: .
@prefix version: .
@prefix instance: .
@prefix process: .
@prefix np: .
@prefix rdfs: .
@prefix xsd: .
@prefix has-source: .
@prefix d: .
@prefix dv: .
@prefix dr: .
@prefix npx: .
sub:head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:publicationInfo;
a np:Nanopublication .
}
sub:assertion {
d:DB00479 dv:ddi-interactor-in dr:DB00479_DB01111 .
d:DB01111 dv:ddi-interactor-in dr:DB00479_DB01111 .
dr:DB00479_DB01111 dcterms:identifier "drugbank_resource:DB00479_DB01111";
dcterms:title "DDI between Amikacin and Colistimethate - Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely."@en;
a dv:Drug-Drug-Interaction;
rdfs:label "DDI between Amikacin and Colistimethate - Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. [drugbank_resource:DB00479_DB01111]"@en .
}
sub:provenance {
sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}
sub:publicationInfo {
sub:signature.MC0CFQCIC-4vfQRg npx:hasPublicKey "MIIBtzCCASwGByqGSM44BAEwggEfAoGBAP1/U4EddRIpUt9KnC7s5Of2EbdSPO9EAMMeP4C2USZpRV1AIlH7WT2NWPq/xfW6MPbLm1Vs14E7gB00b/JmYLdrmVClpJ+f6AR7ECLCT7up1/63xhv4O1fnxqimFQ8E+4P208UewwI1VBNaFpEy9nXzrith1yrv8iIDGZ3RSAHHAhUAl2BQjxUjC8yykrmCouuEC/BYHPUCgYEA9+GghdabPd7LvKtcNrhXuXmUr7v6OuqC+VdMCz0HgmdRWVeOutRZT+ZxBxCBgLRJFnEj6EwoFhO3zwkyjMim4TwWeotUfI0o4KOuHiuzpnWRbqN/C/ohNWLx+2J6ASQ7zKTxvqhRkImog9/hWuWfBpKLZl6Ae1UlZAFMO/7PSSoDgYQAAoGAETGrDm8R3KfndKRj7ttr3jVhhstI6/2Ey0ER9F5kdx7Hrd6eolq7yWzPzf2H754tdZxICzxYcdawBbL2ZUzFjWwXTNUQC3+e6evKPJyNELubnZcA+8TxIIwicBnw3Ku6mSeI8SUVr5SBV1VeJoSu/ahldv562IdBR8IagmzuT3Y=";
npx:hasSignature "MC0CFQCIC+4vfQRgkU5yVjUkI5xyoPqooQIUTeZW6pzRNEexHKsBPBj+EpRec1Y=";
npx:signedBy instance: .
this: dcterms:created "2018-03-30T11:12:34.482+02:00"^^xsd:dateTime;
dcterms:license ;
npx:hasSignatureElement sub:signature.MC0CFQCIC-4vfQRg;
prov:wasGeneratedBy process: .
instance: prov:specializationOf codebase:;
prov:wasAttributedTo orcid:0000-0002-1267-0234 .
process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11";
prov:used version:;
prov:wasAssociatedWith instance:;
prov:wasStartedBy orcid:0000-0002-1267-0234 .
version: dcterms:isVersionOf codebase:;
pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}